EUVIMEDEUVIMED entdecken
Crossref

Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain‐cleavable peptide linker

Yan Wang iD, Liping Wei, Yuan Liu, Cheng Liu, Minbo Hou, Lu Zhou, Le Wang, Hua Li, Yunliang Qiu, JingMa

Journal of Applied Toxicology · 2024

DOI: 10.1002/jat.4622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2024. Verfasst von Yan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacological Evaluation Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China. Hauptthemen laut MEDLINE: Doxorubicin, Rats, Sprague-Dawley. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Innovative New Drug Non-Clinical Research Service Platform of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Legubicin is a novel conjugate of doxorubicin and a legumain‐cleavable peptide linker. It has been developed to ameliorate the side effects of doxorubicin. Biodistribution in tumor‐bearing mice, acute tolerance, and potential systemic toxic effects in Sprague–Dawley rats and beagle dogs of legubicin were assessed. Legubicin exists mainly as a protein complex in plasma after entering the circulation. Compared with conventional doxorubicin at an equal molar dose in mice, we found higher exposure to doxorubicin in tumor (approximately 1.7‐fold increase) while lower exposure in normal tissues (an ~3.26‐, 3.46‐, and 1.29‐fold reduction in heart, kidney, and plasma, respectively) in tumor‐bearing mice after intravenous injection of legubicin. The acute maximum tolerance dose (MTD) of legubicin was >16 mg/kg doxorubicin equivalent in female rats, 11 mg/kg doxorubicin equivalent in male rats (LD50 of conventional doxorubicin is 10.51 mg/kg), and >8 mg/kg doxorubicin equivalent in dogs (MTD of conventional doxorubicin is 1.5 mg/kg). Four‐week repeat‐dose toxicity studies of intravenous legubicin were conducted in rats (5, 10, and 25 mg/kg/dose once weekly) and dogs (3/1.5, 10/5, and 20/10 mg/kg/dose once weekly); the dose levels were reduced from the second dose due to intolerable legubicin‐associated toxicity at 20 mg/kg. Major organs of toxicity included the gastrointestinal tract, lymphoid and hematopoietic organs, kidney, skin, liver, reproductive organs, and peripheral nerves, which are all associated with doxorubicin. However, cardiotoxicity was only noted at MTD dose levels. Altogether, our results confirm an improved safety profile of legubicin over conventional doxorubicin and support its clinical benefit for treating cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinRats, Sprague-DawleyAnimalsTissue DistributionFemaleMaleDogsRatsMiceCysteine EndopeptidasesMaximum Tolerated DoseLethal Dose 50Antineoplastic AgentsAntibiotics, AntineoplasticAsparaginyl Endopeptidase

Stichwörter der Autor:innen

conjugate of doxorubicin and a legumain‐cleavable peptide linkerdoxorubicinlegumainnonclinical safetyprodrug

Substanzen

DoxorubicinCysteine EndopeptidasesAntineoplastic AgentsAntibiotics, AntineoplasticAsparaginyl Endopeptidase

Autor:innen und Institutionen

  • Pharmacological Evaluation Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China.
  • Department of toxicology, Shanghai InnoStar Bio-tech Co, Ltd (InnoStar), Shanghai, China.
  • Shanghai Affinity Bio-Pharmaceuticals Co, Ltd, Shanghai, China.

ORCID-Profile: Yan Wang

Förderung

  • Innovative New Drug Non-Clinical Research Service Platform of Shanghai

Zitieren

APA

Wang, Y., Wei, L., Liu, Y., Liu, C., Hou, M., Zhou, L., Wang, L., Li, H., Qiu, Y., & JingMa (2024). Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain‐cleavable peptide linker. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4622

Vancouver

Wang Y, Wei L, Liu Y, Liu C, Hou M, Zhou L, et al. Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain‐cleavable peptide linker. Journal of Applied Toxicology. 2024. doi:10.1002/jat.4622

BibTeX
@article{Wang2024,
  author = {Wang, Yan and Wei, Liping and Liu, Yuan and Liu, Cheng and Hou, Minbo and Zhou, Lu and Wang, Le and Li, Hua and Qiu, Yunliang and JingMa},
  title = {Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain‐cleavable peptide linker},
  journal = {Journal of Applied Toxicology},
  year = {2024},
  doi = {10.1002/jat.4622}
}
Kostenlos starten →